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1 |  INTRODUCTION
Systemic lupus erythematosus (SLE) remains a disease of 
unknown etiology with a mosaic of clinical presentations. 
Cutaneous lesions are a first sign of SLE in up to one quarter 
of patients.1 According to histopathologic criteria, cutaneous 
manifestations include lupus erythematosus (LE)‐specific 
and LE‐nonspecific lesions. LE‐specific lesions are subdi-
vided according to clinical phenotype, histological changes, 
laboratory abnormalities, and average duration. As the clini-
cal and histological features of SLE skin lesions may mimic 
many other dermatological conditions, a skin biopsy may be 
required and a correct diagnosis relies on strict clinico‐patho-
logical correlation, benefiting from evaluation by a lupus 
expert or an experienced dermatopathologist.1-3 We hereby 
describe diagnostic and management difficulties and a suc-
cessful therapeutic outcome in a single SLE patient, applying 
current knowledge to discuss a multiplicity of cutaneous 
lesions.
2 |  CASE REPORT
In April 2012, a previously healthy 12‐year‐old female pre-
sented with a malar rash (Figure 1A). Menarche had started at 
11 years of age, and the patient had been vaccinated according 
to the national Portuguese vaccination program including the 
first dose of the human papilloma virus vaccine, administered 
1 month before symptom onset. The clinical characteristics, 
histological reports, treatments, and outcome are presented in 
chronological order in Tables 1 and 2. A skin biopsy (Figure 
2A) was reported as compatible with a diagnosis of lupus. More 
specifically, there was a thin epidermis, the basement mem-
brane was not thickened, and a mild perivascular lymphocytic 
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Key Clinical Message
The report highlights the importance of strict clinico‐histological correlations when 
skin biopsies are performed in diagnostic doubt in systemic lupus erythematosus. 
Furthermore, PUVA is never indicated in autoimmune conditions involving photo-
sensitivity, due to high potential for internal and cutaneous aggravation of the dis-
ease, as the authors observed in this case.
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infiltrate and focal vacuolization were found at the dermoe-
pidermal junction. Edema, vessel ectasia, a mild perivascu-
lar lymphocytic infiltrate, and mucin deposits were found in 
the reticular dermis and a lymphocytic infiltrate surrounded 
hair follicles. At that time anti‐SSA antibodies were present, 
but there were no other abnormalities in the full blood count, 
renal function, or urinary sediment. There was improvement 
with topical hydrocortisone, tacrolimus, and photoprotection. 
One month later, the patient developed fever and lost 1.5 kg 
in weight, and 3 months later, the rash on the cheeks returned 
(Figure 1B). Repeat biopsies in the malar region were per-
formed in July 2012 but a tissue orientation error prevented in-
terpretation. At that time, a lupus band test from unaffected skin 
revealed the presence of IgM and IgG granular deposits in the 
basement membrane. Hydroxychloroquine (HCQ) 400 mg/d 
was started and the rash improved (Figure 1C). Despite HCQ, 
in December 2012, symmetrical painful violaceous lesions ap-
peared on the tip of the fingers and toes. These resolved with 
deflazacort 30 mg/d for 1 week, progressively discontinued in 
the following 3 months. In June 2013, still on HCQ, worsening 
of the malar rash was documented. In April 2014, the patient 
reported the onset of pruritic well‐defined hyperkeratotic pap-
ules initially in the lower limbs, rapidly spreading to the but-
tocks, upper torso, arms, palms of hands and scalp, resulting 
in severe alopecia (Figure 1D). The complete full blood count, 
hepatic and renal function tests were within normal ranges. A 
more extensive profile revealed ANA positivity (1/1280), with 
an elevated anti‐dsDNA, a low C4 and C3. The patient was 
then treated with daily deflazacort 30 mg, azathioprine (AZA) 
50 mg and anti‐histaminics, with no improvement. At that 
time, scabies was suspected and topical treatment with ben-
zyl benzoate was prescribed on two occasions. Several scalp 
punch biopsies in September 2014 (Figure 2B) were reported 
as compatible with lupus, folliculitis being reported in one of 
the samples (Figure 2C). No periodic acid‐Schiff (PAS) posi-
tive microorganisms were identified, and there was no immu-
noglobulin deposition by direct immunofluorescence. The 
skin condition progressively deteriorated, and both deflazacort 
and AZA were discontinued. Several discordant histologi-
cal diagnosis of perforating dermatosis (Figure 2D) and pso-
riasis (Figure 2E) ensued. The patient was then treated with 
oral isotretinoin, whole body psoralen, and ultraviolet‐A light 
therapy (PUVA), 3 times a week (oral 8‐Methoxsalen admin-
istered before each session with initial, final and total doses 
of 1.5, 9, and 29.5 J/cm2, respectively). These treatments were 
harmful and stopped after eleven sessions due to the develop-
ment of generalized, erosive, painful and extremely pruritic 
disseminated cutaneous lesions with severe alopecia (Figure 
1E), after which the patient was admitted to our unit in July 
2015. Laboratory tests showed leucopenia (3100/μL), neutro-
penia (1680/μL), ANA positivity (1/640), anti‐dsDNA antibod-
ies (277 IU/mL; ELISA reference: <25 IU/mL), complement 
consumption (C3 = 61 mg/dL [normal range: 90‐180 mg/
dL], C4 = 5 mg/dL [normal range: 10‐40 mg/dL]), and sus-
tained proteinuria (highest value: 1006 mg/24 h). ELISA tests 
for anti‐Beta‐2 Glycoprotein1 and anti‐cardiolipin antibodies 
as well as the lupus anticoagulant assay were negative. The 
renal biopsy revealed class V membranous glomerulonephritis 
with granular deposits of immunoglobulins, complement com-
ponents, and light chains (Figure S1); tissue and serum anti‐
Phospholipase A2 receptor antibody were negative. In view 
of her skin condition, off‐label intravenous immunoglobulin 
(IVIG) was administered (20 g/d × 5 days) together with HCQ 
400 mg/d, and mycophenolate mofetil (MMF) was started at 
the dose of 500 mg bd and increased weekly by 250 mg bd 
to a maximum dose of 1 g bd, together with enalapril 5 mg/d. 
On the 20th day of hospitalization due to the ongoing sever-
ity of the skin lesions, the patient was treated with rituximab 
F I G U R E  1  Clinical features. Age 12—cutaneous lesions localized to malar regions (A and B); topical treatment led to improvement without 
scarring (C); Age 14—generalized rash, started in legs and extending to arms, buttocks, palm of hands and fronto‐temporal regions of the scalp 
with alopecia (D); Age 15—post PUVA (E); Age 15—post rituximab (F)
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(RTX) 1 g preceded by methylprednisolone 500 mg, on days 
1 and 15, in addition to the above‐mentioned drugs. The skin 
rash resolved within 2 weeks of the RTX administration, with 
residual hypopigmentation (Figure 1C); full hair re‐growth 
was documented at 6 months (Figure 1D) with well‐being and 
sustained renal remission at 3 years of follow‐up, allowing for 
successful medication taper (Figure 3), continuing HCQ and 
MMF as maintenance treatment.
3 |  DISCUSSION AND 
CONCLUSIONS
In contrast to lupus nephritis where a renal biopsy has 
prognostic and therapeutic value with a classification 
based on well‐recognized features,4 when lupus affects 
the skin, lesions cannot be distinguished on the grounds 
of histology alone.1 Classically, in most cases of SLE, 
mucin deposition in the dermis is reportedly prominent. 
Findings may be subtle, with discrete basal cell liquefac-
tive degeneration, papillary dermal edema and perivascu-
lar and perifollicular mild chronic inflammatory infiltrate, 
indistinguishable from subacute cutaneous lupus ery-
thematosus (SCLE) and discoid lupus erythematosus 
(DLE).5,6 There are, however, histopathological features 
that are more frequent in some cutaneous subtypes.7 We 
envisage the following scenario based on a retrospective 
clinico‐pathological correlation: In April 2012, at disease 
onset, the patient may have presented with acute cutane-
ous lupus erythematosus (ACLE), suggested by a scaly 
localized malar rash. Nevertheless, this was somewhat 
atypical for ACLE, as the rash was very discrete, there 
F I G U R E  2  Histological features. Temporal correlation with photographs in Figure 1 per lesion: Age 12—localized to malar regions (A); Age 
14—scalp (B), pre‐tibial (C); Age 15—pre‐tibial, pre PUVA (D); Age 15—trunk, post PUVA (E)
(A) (B) (B) (C) (D) (E)
(A) (B) (B) (C) (D) (E)
F I G U R E  3  Follow‐up disease activity  measured by the safety of estrogens in lupus national assessment‐systemic lupus erythematosus 
disease activity index (SELENA‐SLEDAI) and therapy.
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were no systemic features and the lack of scarring after 
healing was against a diagnosis of DLE. The findings 
of perivascular and periadnexal lymphocytic infiltration 
together with mucin deposits, no epidermal change and 
no thickened basement membrane, were in favor of lupus 
erythematosus tumidus (LET). The latter corresponded to 
the morphology of the lesions, characterized by symmetri-
cal erythematous and edematous plaques with a smooth 
surface and no scales, registered 3 months later, in July 
2012. Although HCQ was started, the patient presented 
8 months later with a rash on the tip of the fingers and 
toes suggestive of chilblain lupus. Almost 1 year later, in 
June 2013, the skin lesions worsened on the face, possibly 
due to ACLE or LET, as there was no residual scarring. 
From April 2014, we believe the patient presented with 
SCLE and SLE, on the basis of papulosquamous lesions 
that spared the central face and laboratory findings. These 
lesions were highly pruritic, psoriasiform, and not ex-
clusive to sun‐exposed areas. By September 2014, histo-
logical findings (orthokeratosis and follicular plugs) were 
suggestive of scalp DLE leading to intensification of im-
munosuppression. From then on, a combination of atypi-
cal features (the highly pruritic and psoriasiform nature 
of the lesions), misleading clinical information and re-
fractoriness to therapy distanced the diagnostic path away 
from SLE, the underlying disease. Several misdiagnosis 
including scabies, folliculitis, a histological diagnosis of 
reactive perforating collagenosis vs perforating folliculitis 
and even psoriasis were evoked at the time, leading to an 
incorrect treatment choice with PUVA, with severe del-
eterious consequences. At the time of PUVA treatments, 
we propose the patient was affected by SCLE, with gen-
eralized skin lesions on the entire integument, in addition 
to SLE. Complete healing with no alopecia and no scar-
ring contradict the diagnosis of scalp DLE. Finally, the 
hypopigmentation that remained after healing was typical 
for photosensitive SCLE. In summary, the patient seems 
to have developed several lupus‐specific skin lesions over 
time, starting at least 2 years before the criteria for the di-
agnosis of SLE were fulfilled.8,9 Different manifestations 
appeared over time. Initially, ACLE/LET responding fa-
vorably to HCQ, immunosuppressants, and sunscreen, and 
subsequently, SCLE, refractory to therapy. Contrarily to 
its reportedly favorable prognosis,10 LET seems to have 
preceded SLE in this patient. Of note, PUVA treatment is 
a formal contraindication in patients with photosensitivity.
Metabolic disorders and chronic pruritis may be associ-
ated with reactive perforating dermatosis. This is a variant 
of prurigo nodularis, histologically characterized by epider-
mal perforation11 for which ultraviolet (UV) light therapy 
is recommended.12 But there was no evidence of epidermal 
perforation and not unexpectedly, in this patient, UV light 
therapy was equivalent to a major form of photoprovocation, 
with a deleterious effect, aggravating pre‐existing and pre-
cipitating new cutaneous lesions, followed by a renal flare. 
Furthermore, lesions affecting the palms would not be ex-
pected to occur in any type of folliculitis. The use of IVIG 
was justified by the severity of the presentation. The positive 
long‐term response to rituximab with a steroid sparing ef-
fect has been previously described,13,14 contrasting with the 
adverse events associated to the prolonged use of systemic 
steroids in juvenile SLE patients with skin involvement.15,16
This report emphasizes the divergence of cutaneous 
lupus manifestations that may present in a single patient 
over a period of time and the importance of clinico‐patho-
logical correlation for a correct diagnostic and therapeutic 
approach.
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